body·mind·state
← Back to Research
research

Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial

Psilocybin-assisted therapy has emerged as a promising treatment for major depressive disorder, but little attention has been paid to the psychotherapy that adjoins psilocybin. Providing an adjunctive psychotherapy that is manualized and evidence-bas...

BMS
Body Mind State EditorialJune 15, 2026 · 1 min read

Key Findings

Psilocybin-assisted therapy has emerged as a promising treatment for major depressive disorder, but little attention has been paid to the psychotherapy that adjoins psilocybin. Providing an adjunctive psychotherapy that is manualized and evidence-based may make psilocybin treatment more acceptable, effective, and disseminable. We examined the acceptability, feasibility, and clinical outcomes of psilocybin paired with cognitive behavioral therapy (CBT) for major depressive disorder. Participants were adults with major depressive disorder who presented with at least moderately severe depressive symptoms. All participants underwent psilocybin-assisted CBT (PA-CBT), which consisted of two psilocybin doses (10 mg and 25 mg separated by one month) interspersed with 12 psychotherapy sessions over four months. Participants' depressive symptoms, psychosocial functioning, and cognitive-affective responses were collected at the study's baseline, at the completion of PA-CBT, and three months post-treatment. Sixteen participants were enrolled, and all were retained through the 7-month study. PA-CBT was rated as highly acceptable by participants and study clinicians, with no serious adverse events reported. Based on independent assessments, 13 of 16 participants showed at least moderate (≥ 25%) improvement in depressive symptoms by the end of treatment, and 9 had fully remitted. Pre-to-post treatment improvements in depressive symptoms and psychosocial functioning were sustained at the 3-month follow-up (Hedges' gs = 1.9-2.7). Changes in depressive severity during the treatment were associated with improvements in emotion regulation and positive and negative cognitive schemas. CBT appears to be a feasible, well-accepted, and beneficial adjunct to psilocybin treatment. Future randomized trials are needed to compare the efficacy of PA-CBT with other psilocybin-assisted therapy modalities.

Why This Matters for Body-Mind Practice

[Draft — editorial context needed]

Source

Continue Reading

research

Mechanisms Underlying Burning Mouth Syndrome and Occlusal Dysesthesia: Shared and Distinct Pathways of Oral Sensory Dysregulation

Burning mouth syndrome (BMS) and occlusal dysesthesia (OD) are chronic oral sensory disorders that present without evident local pathology yet frequently cause substantial diagnostic and therapeutic challenges in oral medicine practice. Although both...

1 min read research

Comparative response patterns and tolerability of high-frequency rTMS in unipolar versus bipolar depression: a retrospective naturalistic study

This retrospective naturalistic study compared response patterns and tolerability of high-frequency left-DLPFC repetitive transcranial magnetic stimulation (rTMS) in patients with major depressive disorder (MDD) and bipolar depressive disorder (BD) u...

2 min read research

Cross-cultural translation, adaptation, and validation of the Chinese versions of the athlete fear avoidance questionnaire and fear of return to sport scale

Sports injuries not only impose periods of physical rest, but they can also provoke negative psychological responses, particularly fear, that can delay return to sport (RTS) and elevate reinjury risk. Although various instruments, including the Athle...

1 min read